{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:44:03Z","timestamp":1782701043302,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ejogrb.2025.01.038","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:17:07Z","timestamp":1738063027000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety of niraparib-based regimens in patients with ovarian cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"307","author":[{"given":"Muhammad","family":"Tayyab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair Ahmed","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kondraju Preethi","family":"Kamala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareeda","family":"Brohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushah","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwah Nasir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armanveer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ebad","family":"Ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mislav","family":"Miku\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Simone","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"93","key":"10.1016\/j.ejogrb.2025.01.038_b0005","first-page":"937","article-title":"Diagnosis and management of ovarian cancer","volume":"1","author":"Doubeni","year":"2016","journal-title":"Am Fam Physician"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.01.038_b0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"30","author":"Momenimovahed","year":"2019","journal-title":"Int J Women\u2019s Health"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0015","doi-asserted-by":"crossref","unstructured":"Jorgensen K, Wang V, Schorge J. Ovarian Cancer. DeckerMed Obstetrics and Gynecology. 2019 Sep 24.","DOI":"10.2310\/OBG.19171"},{"issue":"14","key":"10.1016\/j.ejogrb.2025.01.038_b0020","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3390\/cancers14092230","article-title":"Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study","volume":"29","author":"Huang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0025","doi-asserted-by":"crossref","unstructured":"Siegel R, Giaquinto A, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024 Jan 17;74.","DOI":"10.3322\/caac.21820"},{"issue":"19","key":"10.1016\/j.ejogrb.2025.01.038_b0030","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-019-6139-6","article-title":"Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis","volume":"22","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"issue":"91","key":"10.1016\/j.ejogrb.2025.01.038_b0035","first-page":"561","article-title":"Ovarian cancer: an overview","volume":"1","author":"Penny","year":"2020","journal-title":"Radiol Technol"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0040","first-page":"13","article-title":"Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research","volume":"21","author":"Kipps","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.ejogrb.2025.01.038_b0045","doi-asserted-by":"crossref","first-page":"133s","DOI":"10.1200\/JCO.2003.01.066","article-title":"Current status of taxane and platinum-based chemotherapy in ovarian cancer","volume":"1","author":"Mcguire","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19 Suppl 2","key":"10.1016\/j.ejogrb.2025.01.038_b0050","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/IGC.0b013e3181c14007","article-title":"Consolidation therapy in ovarian cancer","volume":"1","author":"Sabbatini","year":"2009","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0055","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","author":"Ison","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0060","doi-asserted-by":"crossref","unstructured":"Akay M, Funingana G, Patel G, Mustapha R, Xhafa-Hamiti E, Ng T, et al. An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions. 2021 Aug 7.","DOI":"10.1007\/s40487-021-00167-z"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0065","first-page":"14","article-title":"The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China","volume":"17","author":"Ni","year":"2021","journal-title":"J Ovarian Res"},{"issue":"14","key":"10.1016\/j.ejogrb.2025.01.038_b0070","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","article-title":"Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer","volume":"1","author":"Saif","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"166","key":"10.1016\/j.ejogrb.2025.01.038_b0075","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0090-8258(22)01298-7","article-title":"Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)","volume":"1","author":"Li","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0080","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2024 Sep 7]. Available from: https:\/\/training.cochrane.org\/handbook."},{"issue":"372","key":"10.1016\/j.ejogrb.2025.01.038_b0085","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"366","key":"10.1016\/j.ejogrb.2025.01.038_b0090","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0095","unstructured":"Ottawa Hospital Research Institute [Internet]. [cited 2024 Sep 7]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"13","key":"10.1016\/j.ejogrb.2025.01.038_b0100","article-title":"A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China","volume":"8","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2023.11.037","article-title":"Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer","volume":"181","author":"Kim","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.01.038_b0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jjco\/hyad125","article-title":"Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer","volume":"54","author":"Nakamura","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejogrb.2025.01.038_b0115","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.01.038_b0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.ejogrb.2025.01.038_b0125","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.01.038_b0130","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment With niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejogrb.2025.01.038_b0135","article-title":"What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China","volume":"18","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.01.038_b0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J Ovarian Res"},{"issue":"8","key":"10.1016\/j.ejogrb.2025.01.038_b0145","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.01.038_b0150","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.01.038_b0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety Profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.01.038_b0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12957-020-01931-7","article-title":"The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2020","journal-title":"World J Surg Onc"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0165","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192226","article-title":"Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials","author":"Shao","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0170","unstructured":"Raedler LA. Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 2018 Apr 10 [cited 2024 Sep 5]; Available from: https:\/\/www.ahdbonline.com\/issues\/2018\/april-2018-vol-11-ninth-annual-payers-guide\/zejula-niraparib-first-parp-inhibitor-approved-for-maintenance-treatment-of-recurrent-ovarian-fallopian-tube-or-primary-peritoneal-cancer."},{"key":"10.1016\/j.ejogrb.2025.01.038_b0175","unstructured":"Niraparib. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [cited 2024 Sep 5]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548333\/."},{"key":"10.1016\/j.ejogrb.2025.01.038_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105808","article-title":"Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis","volume":"172","author":"Cai","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0185","doi-asserted-by":"crossref","unstructured":"Thein KZ, Sultan A, Zaw M, Swarup S, Han MM, Myat YM, et al. Discontinuation of poly(adenosine diphosphate-ribose) polymerase inhibitors due to adverse events in patients with recurrent ovarian cancer: A meta-analysis of three phase III trials. JCO. 2018 Dec;36(34_suppl):118\u2013118.","DOI":"10.1200\/JCO.2018.36.34_suppl.118"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.01.038_b0190","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.01.038_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Targ Oncol"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0200","article-title":"Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0205","doi-asserted-by":"crossref","unstructured":"Wang H, Wu M, Liu H, Zhou H, Zhao Y, Geng Y, et al. Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Front Oncol [Internet]. 2021 Nov 24 [cited 2024 Sep 5];11. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2021.785102\/full.","DOI":"10.3389\/fonc.2021.785102"},{"key":"10.1016\/j.ejogrb.2025.01.038_b0210","article-title":"Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis","author":"Luo","year":"2022","journal-title":"Front Oncol [Internet]"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.01.038_b0215","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/cdd.2014.202","article-title":"PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors","volume":"22","author":"Farr\u00e9s","year":"2015","journal-title":"Cell Death Differ"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:14:42Z","timestamp":1769843682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"alternative-id":["S0301211525000466"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.01.038","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of niraparib-based regimens in patients with ovarian cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}